Clinical Trials
24 trialsNCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT03995888 2026-02-12
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Phase 1 Completed
NCT04186845 2025-09-22
Spotlight
Blue Earth Diagnostics
Phase 3 Completed
NCT05333432 2025-06-25
HRPCa-II
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT06754085 2024-12-31
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd.
Phase 3 Recruiting
NCT06683066 2024-11-12
Study on Human Bioequivalence of Triprerelin Acetate for Injection
The Affiliated Hospital of Qingdao University
Phase 1 Recruiting
NCT06343077 2024-04-02
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT04528199 2024-01-16
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT05140512 2023-05-16
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05856630 2023-05-12
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.
Phase 1 Unknown
NCT03709550 2022-10-05
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT04563936 2021-08-26
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 3 Completed
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02647983 2020-01-22
Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
Sunnybrook Health Sciences Centre
Phase 1 Withdrawn
NCT02238366 2019-07-25
CHRONOS3
Ipsen
Completed
NCT02584400 2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2 Terminated
NCT01993160 2017-01-13
18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer
University Health Network, Toronto
Phase NA Completed
NCT01481441 2016-07-06
AMC_2011_190
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Terminated
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT01229618 2015-10-05
Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer
University of California, San Francisco
Phase 1 Completed